Your browser does not fully support modern features. Please upgrade for a smoother experience.
Tyrosine Kinase Inhibitor: Comparison
Please note this is a comparison between Version 2 by Yu Peng and Version 1 by Yu Peng.

A tyrosine kinase inhibitor is a compound that suppresses the transfer of phosphate from ATP to tyrosine residues in protein substrates by a tyrosine kinase [1]. Targets include membrane-associated receptor kinases and intracellular nonreceptor kinases involved in cellular signaling. Many inhibitors occupy the ATP-binding region, whereas others bind an allosteric site and stabilize a kinase conformation with reduced catalytic activity [1][2]. Binding can be reversible or involve covalent modification of an appropriately positioned amino acid residue [2]. Individual compounds differ in their recognition of kinase conformations and neighboring binding pockets, producing different selectivity profiles across related enzymes [1][2]. Gefitinib inhibits the epidermal growth factor receptor kinase, with particular receptor mutations associated with increased cellular sensitivity [3]. Conversely, changes in the inhibitor-binding region or amplification of the kinase gene can restore signaling despite drug exposure, as demonstrated for BCR–ABL and imatinib [4]. Reduced tyrosine phosphorylation therefore reflects both inhibitor–kinase binding and the molecular state of the targeted signaling system [1][4].

  • tyrosine phosphorylation
  • ATP-binding site
  • kinase selectivity
  • allosteric inhibition

Cancer therapeutics and mechanisms • Molecular Biology • Biochemistry, Genetics and Molecular Biology • Life Sciences

References

  1. Jianming Zhang; Priscilla L. Yang; Nathanael S. Gray; Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 2009, 9, 28-39. [CrossRef]
  2. Joachim Rudolph; Klaus P. Hoeflich; Arvin C. Dar; Contemporary design of small-molecule kinase modulators: orthosteric, allosteric and induced-proximity strategies. Nat. Rev. Drug Discov. 2026, 25, 595-618. [CrossRef]
  3. J. Guillermo Paez; Pasi A. JänNe; Jeffrey C. Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J. Kaye; Neal Lindeman; Titus J. Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J. Eck; William R. Sellers; Bruce E. Johnson; Matthew Meyerson; EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. Science 2004, 304, 1497-1500. [CrossRef]
  4. Mercedes E. Gorre; Mansoor Mohammed; Katharine Ellwood; Nicholas Hsu; Ron Paquette; P. Nagesh Rao; Charles L. Sawyers; Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification. Science 2001, 293, 876-880. [CrossRef]
More
Write an Entry